Novartis: Leukemia, Myelogenous, Chronic, BCR-ABL Positive trials
The registry lists 92 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies with Novartis as lead sponsor. 10 are open to participants now and 37 have results posted.
Phase 1 16Phase 2 26Phase 3 20Phase 4 13No phase 24(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf RegionNot yet recruitingNCT07681258
- A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in GermanyRecruitingNCT07549516
- A Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patients in KuwaitNot yet recruitingNCT07454850
- Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in ChinaRecruitingNCT07375355
- Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPRecruitingNCT07354074Phase 2
- RWE,NIS,Prospective Study for the Effectiveness, Tolerability and Adherence of Asciminib in Saudi Arabia. (ASC4REAL)RecruitingNCT06684964
- Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.RecruitingNCT06514534Phase 2
- Asciminib RMP StudyRecruitingNCT05943522
- Asciminib Roll-over StudyRecruitingNCT04877522Phase 4
- Managed Access Programs for ABL001, AsciminibAvailableNCT04360005
- A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)Active, not recruitingNCT05456191Phase 3Results posted
- A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPActive, not recruitingNCT04971226Phase 3Results posted
- Asciminib Treatment Optimization in ≥ 3rd Line CML-CPCompletedNCT04948333Phase 3Results posted
- Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.CompletedNCT03578367Phase 2Results posted
- Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIsCompletedNCT03106779Phase 3Results posted
- Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.CompletedNCT02546674Phase 4Results posted
- A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic PhaseCompletedNCT02272777Phase 3Results posted
- Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to NilotinibTerminatedNCT02115386Phase 3Results posted
- Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.TerminatedNCT02108951Phase 3Results posted
- Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.CompletedNCT01844765Phase 2Results posted
- Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) PatientsCompletedNCT01784068Phase 2Results posted
- A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment CessationCompletedNCT01744665Phase 2Results posted
- A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.CompletedNCT01743989Phase 3Results posted
- Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the InvestigatorCompletedNCT01742299Phase 4Results posted
- Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored StudyCompletedNCT01735955Phase 4Results posted
- Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)CompletedNCT01698905Phase 2Results posted
- Safety and Tolerability of HSC835 in Patients With Hematological MalignanciesCompletedNCT01474681Phase 1/2Results posted
- Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP PatientsCompletedNCT01275196Phase 3Results posted
- Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)CompletedNCT01274351Phase 2Results posted
- Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia PatientsCompletedNCT01254188Phase 3Results posted
- CMR Rate of Newly Diagnosed CML-CP Patients Treated With NilotinibCompletedNCT01227577Phase 4Results posted
- A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)CompletedNCT01077544Phase 1Results posted
- Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal ResponseCompletedNCT01043874Phase 4Results posted
- An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib TreatmentCompletedNCT00980018Phase 4Results posted
- Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to ImatinibCompletedNCT00802841Phase 3Results posted
- Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)CompletedNCT00760877Phase 3Results posted
- Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to ImatinibTerminatedNCT00644878Phase 2Results posted
- Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)TerminatedNCT00519090Phase 3Results posted
- A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)CompletedNCT00471497Phase 3Results posted
- Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic PhaseTerminatedNCT00451035Phase 2Results posted
- Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast PhaseTerminatedNCT00449761Phase 2Results posted
- Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous LeukemiaCompletedNCT00333840Phase 3Results posted
- An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ LeukemiaCompletedNCT00171249Phase 2Results posted
- An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-AlphaCompletedNCT00171223Phase 2Results posted
- An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast CrisisCompletedNCT00171158Phase 2Results posted
- Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)TerminatedNCT00124748Phase 3Results posted
- A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic MalignanciesCompletedNCT00109707Phase 1/2Results posted
- Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of TreatmentCompletedNCT07188428
- A Real-world Study About the Impact of Adverse Events (AEs) on Treatment Adjustments, Healthcare Resource Use, and Costs Among Chronic Myeloid Leukemia PatientsCompletedNCT07151820
- A Study of Real-world Treatment and Burden of Chronic Myeloid Leukemia Patients in JapanCompletedNCT07150793
- Real-World Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia in Earlier Lines of TherapyCompletedNCT06692803
- Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I MutationCompletedNCT06427811Phase 4
- Real-world Effectiveness of Asciminib and Treatment Patterns in Patients With Chronic Myeloid Leukemia With T315I Mutation - a Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP)CompletedNCT06211153
- Real-World Usage of Asciminib Among Patients With Chronic Myeloid Leukemia in Chronic Phase in the United States Using a Large Claims DatabaseCompletedNCT06148493
- Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in FranceActive, not recruitingNCT06092879
- Real-World Disease Management and Outcomes in Chronic Myeloid LeukaemiaCompletedNCT05893836
- Nilotinib for Patients With Chronic Myeloid Leukemia in First Line and Any Subsequent LineCompletedNCT05734053
- French Study to Highlight the Unmet Treatment Needs of 3L+ CP-CML and With T315I-mutated CML PatientsCompletedNCT05619978
- Clinical Outcomes of 3L+ Therapies Among Patients With Chronic Myeloid Leukemia and Those With T315I MutationCompletedNCT05611216
- Study Conducted Among Patients With CMLCompletedNCT05476562
- Special Drug Use-results Surveillance of Scemblix TabletsCompletedNCT05421091
- Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid LeukemiaActive, not recruitingNCT04925479Phase 1/2
- Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase InhibitorsCompletedNCT04795427Phase 2
- Nilotinib, for Patients With CML-CP or CML-APNo longer availableNCT04518644
- A Study of Full Treatment-free Remission in Patients With Chronic Myeloid LeukemiaTerminatedNCT03874858Phase 2
- Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL PatientsCompletedNCT02253277Phase 1
- A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALLCompletedNCT02081378Phase 1
- Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.WithdrawnNCT01605981Phase 4
- Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior TherapyCompletedNCT01456676Phase 1
- Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 TrialCompletedNCT01368523Phase 4
- Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)CompletedNCT01279473Phase 1/2
- To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of NilotinibCompletedNCT01223898Phase 1
- Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP)CompletedNCT01220648Phase 1
- A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic PhaseCompletedNCT01126892Phase 3
- Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.TerminatedNCT01066468Phase 1
- Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic PhaseApproved for marketingNCT00905593
- Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic PhaseCompletedNCT00786812Phase 4
- Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)CompletedNCT00428909Phase 1
- Effect of Food on Bioavailability of a Modified Release Formulation of ImatinibCompletedNCT00422825Phase 1
- Effect of Food on Bioavailability of Modified Release Formulations of ImatinibCompletedNCT00420043Phase 1
- Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or IntolerantNo longer availableNCT00413270
- A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALLCompletedNCT00384228Phase 1/2
- Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid LeukemiaNo longer availableNCT00302016
- Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate TherapyCompletedNCT00264160Phase 2/3
- Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)CompletedNCT00237120Phase 3
- Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)CompletedNCT00171899Phase 4
- Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib MesylateCompletedNCT00093639Phase 1/2
- Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00081926Phase 4
- STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast CrisisCompletedNCT00006475Phase 2
- STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous LeukemiaCompletedNCT00006343Phase 3
- STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon AlfaCompletedNCT00006053Phase 2
- STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous LeukemiaCompletedNCT00006052Phase 2